Overview
Liraglutide is available as a clear, colorless solution in subcutaneous injectable dosage form. After more than a decade of research and development, liraglutide has a variety of effects, including promoting islet cell regeneration, lowering blood glucose, reducing body weight, and protecting the cardiovascular system. It is marketed as Victoza and is mainly used to treat type 2 diabetes mellitus. Marketed as Saxenda, it is specifically designed to treat chronic obesity, often as an adjunct to diet and exercise. "Liraglutide is an acylated human glucagon-like peptide-1 (GLP-1) receptor agonist that shares 97% amino acid sequence similarity with human endogenous GLP-1 (7-37), retains the full biological activity of GLP-1, and possesses GLP-1 receptor agonist effects." It is expressed by recombinant DNA in Saccharomyces cerevisiae, and its molecular structure differs from native GLP-1 by only one amino acid. Specifically, two structural modifications were made: lysine at position 34 was replaced by arginine, and a glutamic acid-mediated 16-carbon palmityl fatty acid side chain was added to lysine at position 26.
Interactions between drugs
Liraglutide causes prolonged gastric emptying, which may affect the absorption of concomitant oral agents. In clinical pharmacology, liraglutide had no effect on the absorption of the orally administered drugs tested. However, attention should be paid to the potential consequences of delayed absorption of oral agents when co-administered with liraglutide.
Liraglutide has several pharmacological effects:
1. Protection of islet β cells
2. Effect of weight loss
3. Cardiovascular effects of liraglutide
4. The role of liver protection
Treatment effectiveness of Alzheimer's disease (AD).
Post time: 2025-07-17